Literature DB >> 28122462

Current treatment strategies and nanocarrier based approaches for the treatment and management of diabetic retinopathy.

Kousalya Selvaraj1, Kuppusamy Gowthamarajan1, Veera Venkata Satyanarayana Reddy Karri1, Uday K Barauah1, Vanka Ravisankar1, Gifty M Jojo1.   

Abstract

Diabetic retinopathy (DR) is a leading cause of blindness in all working age groups which contribute to patient's quality of life. Considering the anatomy and physiology of barriers in the eye, the treatment and management of pathologic ocular neovascularization in the posterior segment of the eye in DR is a challenging task. The current and emerging treatment strategies are discussed in this review for better understanding and treatment of the DR. Challenges in conventional therapy and recent developments in nanocarrier based approaches (polymeric, lipid nanoparticles, liposomes and dendrimers) and their advantages in targeting ocular tissues were also discussed in this review.

Entities:  

Keywords:  Diabetic retinopathy; diabetes mellitus; nanoparticles; neovascularization; ophthalmic drug delivery; treatments

Mesh：

Substances：

Year:  2017        PMID： 28122462     DOI： 10.1080/1061186X.2017.1280809

Source DB:  PubMed          Journal:  J Drug Target        ISSN： 1026-7158            Impact factor:   5.121


  6 in total

1.  Contribution of the clock gene DEC2 to VEGF mRNA upregulation by modulation of HIF1α protein levels in hypoxic MIO-M1 cells, a human cell line of retinal glial (Müller) cells.

Authors:  Naoki Kusunose; Takahiro Akamine; Yoshiyuki Kobayashi; Shigeo Yoshida; Kenichi Kimoto; Sai Yasukochi; Naoya Matsunaga; Satoru Koyanagi; Shigehiro Ohdo; Toshiaki Kubota
Journal:  Jpn J Ophthalmol       Date:  2018-09-24       Impact factor: 2.447

2.  MiR-423-5p activated by E2F1 promotes neovascularization in diabetic retinopathy by targeting HIPK2.

Authors:  Qing Xiao; Yinu Zhao; Hongjing Sun; Jia Xu; Wenjie Li; Limo Gao
Journal:  Diabetol Metab Syndr       Date:  2021-12-28       Impact factor: 3.320

3.  Preparation of MED1(transcription mediator subunit) gene nanocarrier and its mechanism of action on liver cell regeneration in chronic acute liver failure.

Authors:  Jinwei Guo; Zhixiang Zhang; Jincan Zhu
Journal:  Bioengineered       Date:  2021-12       Impact factor: 3.269

4.  Silencing cyclophilin A improves insulin secretion, reduces cell apoptosis, and alleviates inflammation as well as oxidant stress in high glucose-induced pancreatic β-cells via MAPK/NF-kb signaling pathway.

Authors:  Tangying Li; Huibiao Quan; Huachuan Zhang; Leweihua Lin; Qianying Ou; Kaining Chen
Journal:  Bioengineered       Date:  2020-12       Impact factor: 3.269

5.  Schizandrin A Protects Human Retinal Pigment Epithelial Cell Line ARPE-19 against HG-Induced Cell Injury by Regulation of miR-145.

Authors:  Yi Dong; Cheng Qian; Guangming Wan; Panshi Yan; Shenzhi Liang; Jiong Wang
Journal:  Mol Ther Nucleic Acids       Date:  2019-10-31       Impact factor: 8.886

Review 6.  Nanoparticle Delivery Systems in the Treatment of Diabetes Complications.

Authors:  Eliana B Souto; Selma B Souto; Joana R Campos; Patricia Severino; Tatiana N Pashirova; Lucia Y Zakharova; Amélia M Silva; Alessandra Durazzo; Massimo Lucarini; Angelo A Izzo; Antonello Santini
Journal:  Molecules       Date:  2019-11-20       Impact factor: 4.411
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.